Professor Tinglong Dai discusses a current cancer drug shortage that was caused by a deplorable foreign manufacturing facility that stopped exporting chemotherapy drugs to the U.S. after an inspection that revealed "a cascade of failures." But it could be worse — 4 Americans have died and 8 have been blinded after using generic eyedrops made in a foreign facility that was never inspected by the . In 2022, the inspected only 6% of the nearly 3,000 foreign drug manufacturing facilities. America relies on these facilities for most of our prescription drugs.
EP 1,160B - Drug Quality and Drug Shortages and What We Can Do About It
Featuring:
As a renowned expert in healthcare analytics and global supply chains, Professor Dai has been quoted hundreds of times in the media, including Associated Press, Bloomberg, CNN, Fortune, New York Times, NPR, USA Today, Wall Street Journal, and Washington Post, and has appeared on national and international TV such as CNBC, PBS NewsHour, and Sky News. In 2021, he was named as one of the World's Best 40 Under 40 Business School Professors by Poets & Quants. Professor Dai's research interests span across healthcare, human-AI interaction, global supply chains, and marketing-operations interfaces. His work has been published in leading journals such as Management Science, M&SOM, Marketing Science, and Operations Research, and has been recognized by Johns Hopkins Discovery Award, INFORMS Public Sector Operations Research Best Paper Award, POMS Best Healthcare Paper Award, and Wickham Skinner Early Career Award (Runner-Up). He is an Associate Editor of Management Science, M&SOM, Health Care Management Science, and Naval Research Logistics and a Senior Editor of Production and Operations Management. He co-chairs the Johns Hopkins Symposium on Healthcare Operations and co-edits the Handbook of Healthcare Analytics: Theoretical Minimum for Conducting 21st Century Research on Healthcare Operations, published by John Wiley & Sons in 2018.
Tinglong Dai
Tinglong Dai is Professor of Operations Management and Business Analytics at the Johns Hopkins Carey Business School, with a joint faculty appointment at the Johns Hopkins School of Nursing. He serves on the leadership team of the Hopkins Business of Health Initiative and the executive committee of the Institute for Data-Intensive Engineering and Science. He joined Carey in 2013 after receiving a PhD in Operations Management/Robotics from Carnegie Mellon.As a renowned expert in healthcare analytics and global supply chains, Professor Dai has been quoted hundreds of times in the media, including Associated Press, Bloomberg, CNN, Fortune, New York Times, NPR, USA Today, Wall Street Journal, and Washington Post, and has appeared on national and international TV such as CNBC, PBS NewsHour, and Sky News. In 2021, he was named as one of the World's Best 40 Under 40 Business School Professors by Poets & Quants. Professor Dai's research interests span across healthcare, human-AI interaction, global supply chains, and marketing-operations interfaces. His work has been published in leading journals such as Management Science, M&SOM, Marketing Science, and Operations Research, and has been recognized by Johns Hopkins Discovery Award, INFORMS Public Sector Operations Research Best Paper Award, POMS Best Healthcare Paper Award, and Wickham Skinner Early Career Award (Runner-Up). He is an Associate Editor of Management Science, M&SOM, Health Care Management Science, and Naval Research Logistics and a Senior Editor of Production and Operations Management. He co-chairs the Johns Hopkins Symposium on Healthcare Operations and co-edits the Handbook of Healthcare Analytics: Theoretical Minimum for Conducting 21st Century Research on Healthcare Operations, published by John Wiley & Sons in 2018.